Application progress of polymyxin in bloodstream infection of drug-resistant Acinetobacter baumannii
10.3760/cma.j.cn121430-20210219-00255
- VernacularTitle:多黏菌素在耐药鲍曼不动杆菌血流感染中的应用进展
- Author:
Shuguang ZHANG
1
;
Liutao SUN
;
Limin SUN
;
Ziyue YANG
Author Information
1. 郑州大学第一附属医院重症医学科/综合ICU（2），河南郑州 450018
- Keywords:
Polymyxin;
Carbapenem-resistant Acinetobacter baumannii;
Bloodstream infection;
Multidrug resistant;
Extensively drug resistant
- From:
Chinese Critical Care Medicine
2021;33(11):1401-1404
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the bloodstream infection rate of Gram-negative bacilli has continued to increase. Among them, drug-resistant bacteria have a higher mortality rate and longer hospital stay, especially the bloodstream infection of carbapenem-resistant Acinetobacter baumannii (CRAB). Polymyxin began to be used clinically in the 1950s and has antibacterial activity against multidrug resistant and poly drug-resistant Gram-negative bacilli. It can also be used as an effective permeation agent for the cell envelope of Gram-negative bacilli. Polymyxin is reserved for microbiologically clear drug-resistant Gram-negative bacilli infections. The World Health Organization classifies polymyxin as an antimicrobial drug with clinical significance for human infections and can be used to treat drug-resistant Acinetobacter baumannii infection. This article reviews the clinical treatment of polymyxin in bloodstream infections of drug-resistant Acinetobacter baumannii, to provide reference for clinical medication.
